Ruchir Dave

Ruchir Dave

Auto-generated profile, based on publicly available information

Ruchir Dave

Department of nephrology and transplantation IKDRC‐ITS Ahmedabad Gujarat India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2022 in Transplant Infectious Disease
Verified
Journal Article
Closed access
HMHari Shankar Meshram
Hari Shankar Meshram
VKVivek Kute
Vivek Kute
HRHemant Rane
Hemant Rane
RDRuchir Dave
Ruchir Dave
SBSubho Banerjee
Subho Banerjee
SCSanshriti Chauhan
Sanshriti Chauhan

12 July 2021 in Transplant Infectious Disease
Verified
Journal Article
Open access
PDF file
HMHari Shankar Meshram
Hari Shankar Meshram
VKVivek B. Kute
Vivek B. Kute
HPHimanshu Patel
Himanshu Patel
SDSudeep Desai
Sudeep Desai
SCSanshriti Chauhan
Sanshriti Chauhan
RDRuchir B. Dave
Ruchir B. Dave
Click on the article title to read more.

6 October 2021 in Transplant Infectious Disease
Verified
Journal Article
Open access
PDF file
SCSanshriti Chauhan
Sanshriti Chauhan
HMHari Shankar Meshram
Hari Shankar Meshram
VKVivek Kute
Vivek Kute
HPHimanshu Patel
Himanshu Patel
SDSudeep Desai
Sudeep Desai
RDRuchir Dave
Ruchir Dave
Introduction: Follow‐up studies of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in kidney transplant recipients (KTR) are scarcely reported.Methods: We studied 142 hospitalized KTR for a median (interquartile range) follow‐up of 9 (8–11) months who recovered from SARS‐CoV‐2 during May 2020 to Dec 2020. The outcomes were to assess persistent symptoms post‐discharge; EuroQoL visual analogue score (EQ‐VAS); EuroQoL 5‐dimension score (E5‐QD‐5L) score and modified medical research dyspnea score (mMRC) at 1 month, 3‐month, and beyond 6 months. Graft outcome was also analyzed.Results: The age of the cohort was 43 (34–69) years and COVID‐19 severity ranged from asymptomatic (4%), mild (50%), moderate (35%) to severe (12%).The most common persistent symptom was fatigue which significantly decreased in the follow‐up (n = 45 [32.3] vs. 10 [7.4] vs. 4 [2.9]; p‐value = 0.001) at 1‐month, 3‐month, and beyond 6 months respectively. Decrement in the mean (standard deviation) EQ‐VAS score from baseline was also improved (28.6 [13] vs. 10.4 [12.5] vs. 7.5 [12.0]; p‐value = 0.012). There was significant improvement in all EQ‐5D‐5L scores in follow‐up. There was no deterioration in mMRC scores during the follow‐up (n = 4, 3% vs. 7, 5% vs. 3, 2%; p‐value = 0.86). Cases requiring oxygen had significantly poorer overall scores initially, but there was no difference at 6 months. All 10 graft losses had oxygen requirement and chronic graft dysfunction at baseline.Conclusion: Our initial assessment reports significant improvement in the quality of life in follow‐up. The majority recovered from allograft dysfunction. Further research is warranted to study the full spectrum of follow‐up.